' Major Advance ' : Sotorasib Benefit Persists in KRAS+ NSCLC ' Major Advance ' : Sotorasib Benefit Persists in KRAS+ NSCLC

The first-in-class KRAS inhibitor showed durable benefit in some patients, but emergence of early resistance requires new combination therapies, investigators say.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news